Heterogeneity in American and European Peripheral Artery Disease Guidelines on Non-statin Lipid-Lowering Therapy and Rivaroxaban

New guidelines of the American College of Cardiology and the American Heart Association (ACC/AHA)[1] and the European Society of Cardiology (ESC)[2] for peripheral artery disease (PAD) present comprehensive frameworks for management. Although both guidelines share thoughtful recommendations based on a review of randomized controlled trials (RCTs), noteworthy discrepancies exist regarding the recommended pharmacotherapies for PAD. We focus on two such areas: Adding non-statin lipid-lowering agents[3] [4] and incorporating low-dose rivaroxaban.[5] [6] [7] [8] We reflect on issues about the selection and interpretation of studies in these guidelines and the opportunity to improve aligning the recommendations with the current best evidence.

Publikationsverlauf

Eingereicht: 14. November 2024

Angenommen: 06. Januar 2025

Accepted Manuscript online:
07. Januar 2025

Artikel online veröffentlicht:
24. Januar 2025

• References

• 1 Gornik HL, Aronow HD, Goodney PP. et al; Writing Committee Members. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2024; 83 (24) 2497-2604
• 2 Mazzolai L, Teixido-Tura G, Lanzi S. et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J 2024; 45 (36) 3538-3700
• 3 Paciullo F, Momi S, Gresele P. PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention. Thromb Haemost 2019; 119 (03) 359-367
• 4 Ortega-Paz L, Franchi F, Angiolillo DJ. The lipid-platelet interplay: unraveling the effects of PCSK9 inhibition on platelet reactivity. Thromb Haemost 2024; 124 (06) 528-532
• 5 Bauersachs R, Zannad F. Rivaroxaban: a new treatment paradigm in the setting of vascular protection?. Thromb Haemost 2018; 118 (S 01): S12-S22
• 6 Galli M, Franchi F, Rollini F. et al. Pharmacodynamic profiles of dual-pathway inhibition with or without clopidogrel versus dual antiplatelet therapy in patients with atherosclerotic disease. Thromb Haemost 2022; 122 (08) 1341-1351
• 7 Weitz JI, Angiolillo DJ, Geisler T, Heitmeier S. Dual pathway inhibition for vascular protection in patients with atherosclerotic disease: rationale and review of the evidence. Thromb Haemost 2020; 120 (08) 1147-1158
• 8 Tangelder MJ, van Hattum ES. Antithrombotic therapy in peripheral artery disease—antiplatelet therapy, anticoagulants, both or none. Thromb Haemost 2010; 104 (02) 196-199
• 9 Bonaca MP, Gutierrez JA, Cannon C. et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol 2018; 6 (12) 934-943
• 10 Pastori D, Farcomeni A, Milanese A. et al. Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (05) 866-875
• 11 Bonaca MP, Nault P, Giugliano RP. et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation 2018; 137 (04) 338-350
• 12 Jukema JW, Szarek M, Zijlstra LE. et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol 2019; 74 (09) 1167-1176
• 13 Clavijo LC, Caro J, Choi J. et al. The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study). Cardiovasc Revasc Med 2023; 55: 1-5
• 14 Sabatine MS, Giugliano RP, Keech AC. et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376 (18) 1713-1722
• 15 Bonaca MP, Bauersachs RM, Anand SS. et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382 (21) 1994-2004
• 16 Eikelboom JW, Connolly SJ, Bosch J. et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
• 17 Kaplovitch E, Eikelboom JW, Dyal L. et al. Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol 2021; 6 (01) 21-29
• 18 Canonico ME, Hess CN, Naveh S. et al. Real-World Prescription of Dual Pathway Inhibition Therapy in Patients with Peripheral Artery Disease Undergoing Lower Extremity Revascularization. Accessed at: https://cpcclinicalresearch.org/wp-content/uploads/2024/10/SVM-2024-Canonico-Real-World-Prescription-of-Dual-Pathway-Inhibition-Therapy-in-Patients-with-Peripheral-Artery-Disease-Undergoing-Lower-Extremity-Revascularization.pdf
• 19 Ortega-Paz L, Franchi F, Rollini F. et al. Switching from dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: the Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) study. Thromb Haemost 2024; 124 (03) 263-273
• 20 Kang DS, Yang PS, Kim D. et al. Racial differences in ischemic and hemorrhagic stroke: an ecological epidemiological study. Thromb Haemost 2024; 124 (09) 883-892
• 21 Kang DS, Yang PS, Kim D. et al. Racial differences in bleeding risk: an ecological epidemiological study comparing Korea and United Kingdom subjects. Thromb Haemost 2024; 124 (09) 842-851
• 22 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432